<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981227</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-207</org_study_id>
    <nct_id>NCT00981227</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia</brief_title>
  <official_title>Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Therapy for Patients With Post-herpetic Neuralgia: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL)
      as therapy for patients with post-herpetic neuralgia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain</measure>
    <time_frame>baseline and 13 weeks</time_frame>
    <description>The primary efficacy variable will be based upon an 11-point (0-10) Numeric Rating Pain Scale (NRPS), where 0 = no pain and 10 = worst possible pain, to be recorded in a patient's diary upon awakening each morning. This score should reflect the patient's mean pain over the previous 24 hours.
Please note that the change from baseline to endpoint in mean pain, i.e. the difference between endpoint mean pain and baseline mean pain, which are defined as follows:
Baseline mean pain is defined as the mean of the last four available ratings of average daily pain (NRPS) in the patient diary performed in the last 7 days before randomisation.
Endpoint mean pain is defined as the mean of the last four available ratings of average daily pain in the patient diary in the last 7 days of the treatment period.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Mean Pain (NRPS) From Baseline to Endpoint by Total Daily Dose</measure>
    <time_frame>baseline and 13 weeks</time_frame>
    <description>Details of neuropathic pain, as recorded in a subject diary, were used for the primary assessment of analgesic efficacy. Subjects assessed their pain using an 11-point (0 &quot;no pain&quot; to 10 &quot;worst possible pain&quot;) NRPS upon awakening each morning and recorded the results in the subject diary. This score reflected the subject's mean pain over the previous 24 hours. Subjects were trained how to record their pain reliably. Investigators were trained in the subject's NRPS use during site initiation visits and at the investigators' meeting.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">567</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>ESL 400 mg twice-daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 400 mg twice-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg once-daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 800 mg once-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 600 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 600 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 1200 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 800 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eslicarbazepine acetate</intervention_name>
    <description>Scored tablets</description>
    <arm_group_label>ESL 400 mg twice-daily</arm_group_label>
    <arm_group_label>ESL 800 mg once-daily</arm_group_label>
    <arm_group_label>ESL 600 mg twice daily</arm_group_label>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <arm_group_label>ESL 800 mg twice daily</arm_group_label>
    <other_name>Zebinix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral route</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in the study

          -  Men and women aged 18 years or older

          -  Previous diagnosis of herpes zoster

          -  Diagnosis of postherpetic neuralgia and neuropathic pain present for more than 3
             months after healing of the herpes zoster skin rash

          -  Cooperation and willingness to complete all aspects of the study

          -  Completion of at least 4 daily diaries during the week preceding randomisation

          -  A minimum average daily pain score of 4 on the NRPS in the last 4 diary entries before
             randomisation.

        Exclusion Criteria:

          -  Pain of other origin that might confound the assessment of neuropathic pain of
             postherpetic origin

          -  Active herpes zoster lesion or dermatitis of any origin at the affected site

          -  Subjects who had neurological ablation by block or neurosurgical intervention for
             control of pain

          -  Significant or unstable medical or psychiatric disorders

          -  Drug or alcohol abuse in the preceding 2 years

          -  Severe renal function impairment, as shown by calculated creatinine clearance values &lt;
             30 mL/min at screening

          -  Relevant clinical laboratory abnormalities (e.g., Na+ &lt;130 mmol/L, alanine (ALT) or
             aspartate (AST) transaminases &gt;2.0 times the upper limit of the normal, white blood
             cell count (WBC) &lt;2,500 cells/mm3)

          -  Previous participation in any study with eslicarbazepine acetate

          -  Pregnancy or breast feeding

          -  History of hypersensitivity to the investigational products or to drugs with a similar
             chemical structure

          -  History of non-compliance

          -  Likelihood of requiring treatment during the study period with drugs or other
             interventions not permitted by the clinical study protocol

          -  Participation in a clinical study within 3 months prior to screening

          -  Any clinical significant concomitant condition which might influence the assessments
             or conduct of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>February 7, 2013</results_first_submitted>
  <results_first_submitted_qc>March 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain herpetic neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled 06 November 2007; Date last subject completed: 19 January 2009.
Number of subjects:
Planned: 540 subjects (90 in each of the 6 treatment groups). Randomised and treated: 567. Analysed for efficacy (per–protocol): 396 Analysed for safety: 567.</recruitment_details>
      <pre_assignment_details>An up to 2–week baseline was followed by a 1–week titration period, an 8–week maintenance period, and a 2–week safety follow–up period. If subjects had a creatinine clearance between 30 and 60 mL/min, they received half of the assigned dose, and subjects with a creatinine clearance below 30 mL/min were not enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ESL 1200 mg Once Daily</title>
          <description>ESL 1200 mg once daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="P2">
          <title>ESL 400 mg Twice-daily</title>
          <description>ESL 400 mg twice-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="P3">
          <title>ESL 600 mg Twice Daily</title>
          <description>ESL 600 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="P4">
          <title>ESL 800 mg Once-daily</title>
          <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="P5">
          <title>ESL 800 mg Twice Daily</title>
          <description>ESL 800 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>placebo
Placebo : oral route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per–Protocol</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ESL 1200 mg Once Daily</title>
          <description>ESL 1200 mg once daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="B2">
          <title>ESL 400 mg Twice-daily</title>
          <description>ESL 400 mg twice-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="B3">
          <title>ESL 600 mg Twice Daily</title>
          <description>ESL 600 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="B4">
          <title>ESL 800 mg Once-daily</title>
          <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="B5">
          <title>ESL 800 mg Twice Daily</title>
          <description>ESL 800 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>placebo
Placebo : oral route</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="94"/>
            <count group_id="B4" value="94"/>
            <count group_id="B5" value="90"/>
            <count group_id="B6" value="93"/>
            <count group_id="B7" value="567"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain</title>
        <description>The primary efficacy variable will be based upon an 11-point (0-10) Numeric Rating Pain Scale (NRPS), where 0 = no pain and 10 = worst possible pain, to be recorded in a patient's diary upon awakening each morning. This score should reflect the patient's mean pain over the previous 24 hours.
Please note that the change from baseline to endpoint in mean pain, i.e. the difference between endpoint mean pain and baseline mean pain, which are defined as follows:
Baseline mean pain is defined as the mean of the last four available ratings of average daily pain (NRPS) in the patient diary performed in the last 7 days before randomisation.
Endpoint mean pain is defined as the mean of the last four available ratings of average daily pain in the patient diary in the last 7 days of the treatment period.</description>
        <time_frame>baseline and 13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ESL 1200 mg Once Daily</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O2">
            <title>ESL 400 mg Twice-daily</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O3">
            <title>ESL 600 mg Twice Daily</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O4">
            <title>ESL 800 mg Once-daily</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O5">
            <title>ESL 800 mg Twice Daily</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>total daily dose;oral route</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain</title>
          <description>The primary efficacy variable will be based upon an 11-point (0-10) Numeric Rating Pain Scale (NRPS), where 0 = no pain and 10 = worst possible pain, to be recorded in a patient's diary upon awakening each morning. This score should reflect the patient's mean pain over the previous 24 hours.
Please note that the change from baseline to endpoint in mean pain, i.e. the difference between endpoint mean pain and baseline mean pain, which are defined as follows:
Baseline mean pain is defined as the mean of the last four available ratings of average daily pain (NRPS) in the patient diary performed in the last 7 days before randomisation.
Endpoint mean pain is defined as the mean of the last four available ratings of average daily pain in the patient diary in the last 7 days of the treatment period.</description>
          <units>Points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9447" spread="0.2088"/>
                    <measurement group_id="O2" value="-1.9786" spread="0.2178"/>
                    <measurement group_id="O3" value="-1.6798" spread="0.2179"/>
                    <measurement group_id="O4" value="-1.6633" spread="0.2217"/>
                    <measurement group_id="O5" value="-2.0834" spread="0.2280"/>
                    <measurement group_id="O6" value="-1.5441" spread="0.2197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Pain (NRPS) From Baseline to Endpoint by Total Daily Dose</title>
        <description>Details of neuropathic pain, as recorded in a subject diary, were used for the primary assessment of analgesic efficacy. Subjects assessed their pain using an 11–point (0 “no pain” to 10 “worst possible pain”) NRPS upon awakening each morning and recorded the results in the subject diary. This score reflected the subject’s mean pain over the previous 24 hours. Subjects were trained how to record their pain reliably. Investigators were trained in the subject’s NRPS use during site initiation visits and at the investigators’ meeting.</description>
        <time_frame>baseline and 13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo
Placebo : oral route</description>
          </group>
          <group group_id="O2">
            <title>ESL 1200 mg/Day</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O3">
            <title>ESL 1600 mg/Day</title>
            <description>total daily dose;oral route</description>
          </group>
          <group group_id="O4">
            <title>ESL 800 mg/Day</title>
            <description>total daily dose;oral route</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pain (NRPS) From Baseline to Endpoint by Total Daily Dose</title>
          <description>Details of neuropathic pain, as recorded in a subject diary, were used for the primary assessment of analgesic efficacy. Subjects assessed their pain using an 11–point (0 “no pain” to 10 “worst possible pain”) NRPS upon awakening each morning and recorded the results in the subject diary. This score reflected the subject’s mean pain over the previous 24 hours. Subjects were trained how to record their pain reliably. Investigators were trained in the subject’s NRPS use during site initiation visits and at the investigators’ meeting.</description>
          <units>Points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5448" spread="0.2196"/>
                    <measurement group_id="O2" value="-1.8183" spread="0.1512"/>
                    <measurement group_id="O3" value="-2.0854" spread="0.2279"/>
                    <measurement group_id="O4" value="-1.8236" spread="0.1565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All TEAEs, i.e. those AEs starting after the first dose intake until 2 days after the last dose,have been summarized</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ESL 1200 mg Once Daily</title>
          <description>ESL 1200 mg once daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="E2">
          <title>ESL 400 mg Twice-daily</title>
          <description>ESL 400 mg twice-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="E3">
          <title>ESL 600 mg Twice Daily</title>
          <description>ESL 600 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="E4">
          <title>ESL 800 mg Once-daily</title>
          <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="E5">
          <title>ESL 800 mg Twice Daily</title>
          <description>ESL 800 mg twice daily
Eslicarbazepine acetate : Scored tablets</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>placebo
Placebo : oral route</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>Bial-Portela &amp; Cª, S.A.</organization>
      <phone>+351 22 986 6100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

